Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 5,000 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $97.45, for a total transaction of $487,250.00. Following the completion of the sale, the chief executive officer owned 2,272,500 shares of the company’s stock, valued at approximately $221,455,125. The trade was a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

iRadimed Price Performance

Shares of NASDAQ:IRMD traded up $1.35 during midday trading on Tuesday, hitting $99.25. The company had a trading volume of 72,289 shares, compared to its average volume of 94,486. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $100.39. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of 60.15 and a beta of 1.09. The business’s 50-day simple moving average is $93.12 and its 200-day simple moving average is $77.35.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The company had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, sell-side analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s payout ratio is 41.21%.

Hedge Funds Weigh In On iRadimed

A number of hedge funds and other institutional investors have recently bought and sold shares of IRMD. CWM LLC increased its stake in iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the period. Quarry LP purchased a new position in shares of iRadimed in the third quarter valued at approximately $40,000. State of Alaska Department of Revenue acquired a new position in shares of iRadimed in the third quarter valued at approximately $47,000. Tower Research Capital LLC TRC increased its stake in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares during the period. Finally, Spire Wealth Management acquired a new stake in iRadimed during the 2nd quarter worth approximately $60,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IRMD has been the subject of a number of recent analyst reports. Roth Capital set a $90.00 price target on shares of iRadimed in a report on Friday, October 31st. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 26th. Zacks Research upgraded iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Lake Street Capital restated a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a report on Monday, November 3rd. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, iRadimed currently has an average rating of “Moderate Buy” and a consensus price target of $87.33.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.